A groundbreaking discovery by scientists at UCLA may soon revolutionize the way we treat hair loss. Researchers have developed a small molecule, known as PP405, that has shown remarkable promise in regenerating hair by reactivating dormant hair follicle stem cells.
Unlike current treatments such as minoxidil or finasteride—which work for some but not all—PP405 targets hair loss at a deeper metabolic level. It awakens “sleeping” hair follicles, enabling them to grow strong, thick hair once again. In early human trials, just one week of applying the molecule showed significant biological responses in the scalp, with signs of visible hair regrowth.
The molecule is being commercialized by Pelage Pharmaceuticals, a UCLA spinout, and has already completed Phase 1 human trials. Now entering Phase 2, researchers are optimistic about bringing this treatment to market within the next few years. The development is being backed by major investors, including Google Ventures.
This discovery is not only a potential game-changer for those struggling with baldness or thinning hair—it also marks a leap forward in stem cell-based regenerative medicine. For millions around the world, this could mean a future where hair loss is no longer permanent, but completely reversible.